Lilly buys ARMO BioSciences for $1.6 billion
Eli Lilly is buying ARMO BioSciences in a deal valued at around $1.6 billion, to ramp up its immune-oncology pipeline.
Read More
Tag: pegilodecakin
- MHRA approves new treatment for severe alopecia areata
- Aplagon doses first patient in phase 2a trial of APAC
- NHS to offer fezolinetant for menopause‑related hot flushes and night‑sweats
- UCB reports superiority of bimekizumab in psoriatic arthritis study
- Kainova reports positive results for DT‑9081 in advanced solid tumours
